← Leaderboards
Harriet M Kluger
Yale University
$18,066,555
Attributed
$25,440,989
Total exposure
18
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.1M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$42,436,318 · 19
By mechanism
P50$21,026,055 · 7
R01$12,192,758 · 6
K12$5,362,363 · 1
R44$1,999,989 · 1
K24$780,420 · 1
P30$774,737 · 2
Top collaborators
- Ruth Halaban12 shared
- Marcus W Bosenberg10 shared
- Gary V. Desir8 shared
- Kevan C Herold7 shared
- Titus Jonathon Boggon6 shared
- Kenneth K. Kidd6 shared
- Joseph Schlessinger6 shared
- Barry A Berkowitz3 shared
Most similar at Yale University
Same institution · by research overlap
- Gil G Mor$13,879,233
- Anne C Chiang$1,338,509
- Ruth Halaban$8,123,059
- Timothy Newhouse$3,085,797
- Roy Decker$1,202,580
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorResponseMalignant NeoplasmsResistanceMelanomaCellsBasePharmaceutical PreparationsResearch PersonnelPathway InteractionsMelanoma CellImmunotherapyProgramsClinical TrialsGrowthSamplingFundingFutureMedical SchoolsYale Cancer CenterNext GenerationTrainingMetastatic MelanomaScience
Grant awards (87)
Yale SPORE in Skin Cancer$1,741,032
P50 · FY2025 · CA
YALE CANCER CENTER CALABRESI IMMUNO-ONCOLOGY TRAINING PROGRAM$783,348
K12 · FY2025 · CA · contact PI
Dual-isotope SPECT imaging and immunophenotyping of immune cells to determine response to immunotherapy$687,157
R01 · FY2025 · CA · contact PI
Immune Therapy for Brain Metastasis$557,726
R01 · FY2025 · CA
Career Enhancement Program$106,812
P50 · FY2025 · CA · contact PI
Yale SPORE in Skin Cancer$1,657,668
P50 · FY2024 · CA
YALE CANCER CENTER CALABRESI IMMUNO-ONCOLOGY TRAINING PROGRAM$783,348
K12 · FY2024 · CA · contact PI
Dual-isotope SPECT imaging and immunophenotyping of immune cells to determine response to immunotherapy$607,955
R01 · FY2024 · CA · contact PI
Immune Therapy for Brain Metastasis$542,905
R01 · FY2024 · CA
Cancer Research Training and Education Coordination$138,487
P30 · FY2024 · CA · contact PI
Yale SPORE in Lung Cancer Career Enhancement Program$95,275
P50 · FY2024 · CA · contact PI
Yale SPORE in Skin Cancer$1,533,274
P50 · FY2023 · CA
Dual-isotope SPECT imaging and immunophenotyping of immune cells to determine response to immunotherapy$668,018
R01 · FY2023 · CA · contact PI
Immune Therapy for Brain Metastasis$583,091
R01 · FY2023 · CA
YALE CANCER CENTER CALABRESI IMMUNO-ONCOLOGY TRAINING PROGRAM$582,392
K12 · FY2023 · CA · contact PI
Yale SPORE in Lung Cancer Career Enhancement Program$92,298
P50 · FY2023 · CA · contact PI
Yale SPORE in Skin Cancer$2,313,558
P50 · FY2022 · CA
The Yale Cancer Center Calabresi Immuno-Oncology Training Program (IOTP)$709,775
K12 · FY2022 · CA · contact PI
Novel Target, New Therapy: Anti- Renalase Antibody for Tumors Resistant to PD-1Inhibitors$672,231
R44 · FY2022 · CA
(8) Mechanisms of autoimmune endocrine diseases in patients receiving checkpoint inhibitors$554,845
R01 · FY2022 · CA
Project 4-Modulating Innate Immunity to Overcome Resistance to PD-1/PD-L1 Blockade$311,178
P50 · FY2022 · CA · contact PI
Yale SPORE in Skin Cancer$178,320
P50 · FY2022 · CA
Cancer Research Career Enhancement and Related Activities$118,999
P30 · FY2022 · CA · contact PI
Yale SPORE in Lung Cancer Career Enhancement Program$95,878
P50 · FY2022 · CA · contact PI
Yale SPORE in Skin Cancer$2,325,000
P50 · FY2021 · CA
Novel Target, New Therapy: Anti- Renalase Antibody for Tumors Resistant to PD-1Inhibitors$1,327,758
R44 · FY2021 · CA
The Yale Cancer Center Calabresi Immuno-Oncology Training Program (IOTP)$832,516
K12 · FY2021 · CA · contact PI
(8) Mechanisms of autoimmune endocrine diseases in patients receiving checkpoint inhibitors$580,072
R01 · FY2021 · CA
Renalase inhibition for treatment of unresectable melanoma$481,477
R01 · FY2021 · CA · contact PI
Project 4-Modulating Innate Immunity to Overcome Resistance to PD-1/PD-L1 Blockade$332,308
P50 · FY2021 · CA · contact PI
Cancer Research Career Enhancement and Related Activities$118,999
P30 · FY2021 · CA · contact PI
Yale SPORE in Lung Cancer Career Enhancement Program$79,770
P50 · FY2021 · CA · contact PI
Yale SPORE in Skin Cancer$52,414
P50 · FY2021 · CA
Yale SPORE in Skin Cancer$2,369,171
P50 · FY2020 · CA
The Yale Cancer Center Calabresi Immuno-Oncology Training Program (IOTP)$907,540
K12 · FY2020 · CA · contact PI
(8) Mechanisms of autoimmune endocrine diseases in patients receiving checkpoint inhibitors$585,633
R01 · FY2020 · CA
Renalase inhibition for treatment of unresectable melanoma$481,894
R01 · FY2020 · CA · contact PI
Project 4-Modulating Innate Immunity to Overcome Resistance to PD-1/PD-L1 Blockade$337,216
P50 · FY2020 · CA · contact PI
Cancer Research Career Enhancement and Related Activities$118,999
P30 · FY2020 · CA · contact PI
Yale SPORE in Lung Cancer Career Enhancement Program$99,247
P50 · FY2020 · CA · contact PI
Yale SPORE in Skin Cancer$2,324,892
P50 · FY2019 · CA
The Yale Cancer Center Calabresi Immuno-Oncology Training Program (IOTP)$632,154
K12 · FY2019 · CA · contact PI
(8) Mechanisms of autoimmune endocrine diseases in patients receiving checkpoint inhibitors$568,064
R01 · FY2019 · CA
Renalase inhibition for treatment of unresectable melanoma$470,539
R01 · FY2019 · CA · contact PI
Project 4-Modulating Innate Immunity to Overcome Resistance to PD-1/PD-L1 Blockade$332,297
P50 · FY2019 · CA · contact PI
Cancer Research Career Enhancement and Related Activities$118,999
P30 · FY2019 · CA · contact PI
(8) Mechanisms of autoimmune endocrine diseases in patients receiving checkpoint inhibitors$81,816
R01 · FY2019 · CA
Cancer Research Career Enhancement and Related Activities$11,905
P30 · FY2019 · CA · contact PI
Yale SPORE in Skin Cancer$2,500,000
P50 · FY2018 · CA
(8) Mechanisms of autoimmune endocrine diseases in patients receiving checkpoint inhibitors$580,767
R01 · FY2018 · CA
Renalase inhibition for treatment of unresectable melanoma$491,209
R01 · FY2018 · CA · contact PI
Project 4-Modulating Innate Immunity to Overcome Resistance to PD-1/PD-L1 Blockade$351,750
P50 · FY2018 · CA · contact PI
Humanized Anti-Renalase Antibodies for Unresectable Melanoma$299,996
R43 · FY2018 · CA
(8) Mechanisms of autoimmune endocrine diseases in patients receiving checkpoint inhibitors$293,469
R01 · FY2018 · CA
The Yale Cancer Center Calabresi Immuno-Oncology Training Program (IOTP)$131,290
K12 · FY2018 · CA · contact PI
Cancer Research Career Enhancement and Related Activities$118,999
P30 · FY2018 · CA · contact PI
Cancer Research Career Enhancement and Related Activities$11,905
P30 · FY2018 · CA · contact PI
Cancer Research Career Enhancement and Related Activities$11,905
P30 · FY2018 · CA · contact PI
Cancer Research Career Enhancement and Related Activities$2,857
P30 · FY2018 · CA · contact PI
Cancer Research Career Enhancement and Related Activities$2,683
P30 · FY2018 · CA · contact PI
Renalase inhibition for treatment of unresectable melanoma$490,257
R01 · FY2017 · CA · contact PI
The RAC1 Pathway as aTarget for Melanoma Therapy$156,681
P50 · FY2017 · CA
A research and training program for junior clinicians in treating metastatic mela$156,084
K24 · FY2017 · CA · contact PI
Molecular Diversity of Melanomas and Response to Targeted Therapy$25,000
P50 · FY2017 · CA
The RAC1 Pathway as aTarget for Melanoma Therapy$156,828
P50 · FY2016 · CA
Molecular Diversity of Melanomas and Response to Targeted Therapy$156,752
P50 · FY2016 · CA
A research and training program for junior clinicians in treating metastatic mela$156,084
K24 · FY2016 · CA · contact PI
Models to Predict Prognosis and Benefit from Adjuvant Therapy in Renal Cell Carci$355,126
R01 · FY2015 · CA · contact PI
The RAC1 Pathway as aTarget for Melanoma Therapy$158,496
P50 · FY2015 · CA
Molecular Diversity of Melanomas and Response to Targeted Therapy$158,420
P50 · FY2015 · CA
A research and training program for junior clinicians in treating metastatic mela$156,084
K24 · FY2015 · CA · contact PI
Models to Predict Prognosis and Benefit from Adjuvant Therapy in Renal Cell Carci$344,260
R01 · FY2014 · CA · contact PI
A research and training program for junior clinicians in treating metastatic mela$156,084
K24 · FY2014 · CA · contact PI
The RAC1 Pathway as aTarget for Melanoma Therapy$155,903
P50 · FY2014 · CA
Molecular Diversity of Melanomas and Response to Targeted Therapy$155,827
P50 · FY2014 · CA
Models to predict prognosis and benefit from adjuvant therapy in renal cell carci$333,177
R01 · FY2013 · CA · contact PI
The RAC1 Pathway as aTarget for Melanoma Therapy$170,344
P50 · FY2013 · CA
Molecular Diversity of Melanomas and Response to Targeted Therapy$170,261
P50 · FY2013 · CA
A research and training program for junior clinicians in treating metastatic mela$156,084
K24 · FY2013 · CA · contact PI
Models to predict prognosis and benefit from adjuvant therapy in renal cell carci$358,148
R01 · FY2012 · CA · contact PI
The RAC1 Pathway as aTarget for Melanoma Therapy$166,133
P50 · FY2012 · CA
Molecular Diversity of Melanomas and Response to Targeted Therapy$166,052
P50 · FY2012 · CA
Models to predict prognosis and benefit from adjuvant therapy in renal cell carci$381,201
R01 · FY2011 · CA · contact PI
Predicting Melanoma Response to BAY 43-9006/Chemotherapy$268,903
R01 · FY2008 · CA · contact PI
Predicting Melanoma Response to BAY 43-9006/Chemotherapy$270,636
R01 · FY2007 · CA · contact PI
Predicting Melanoma Response to BAY 43-9006/Chemotherapy$283,792
R01 · FY2006 · CA · contact PI
Predicting Melanoma Response to BAY 43-9006/Chemotherapy$290,621
R01 · FY2005 · CA